Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06880913 | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | recruiting | Phase 1 | 22 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07107126 | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 24 | Remedy Plan, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04990102 | Phase IB/II of CPX-351 for Relapse Prevention in AML | recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06440135 | Ziftomenib Maintenance Post Allo-HCT | recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05636514 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS(CELESTIAL-MDS) | recruiting | Phase 1 | 12 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | recruiting | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07270770 | BY002 IIT Study in R/R Acute Leukemia | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06994676 | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias(CROSSCHECK-001) | recruiting | Phase 1 | 72 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | recruiting | Phase 1 | 420 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). | recruiting | Phase 1 / Phase 2 | 33 | Gyala TherapeuticsINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05627232 | Tazemetostat and Palbociclib With CPX-351for R/R AML | recruiting | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05535855 | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | recruiting | Phase 1 | 29 | University of Colorado, DenverOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05679895 | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL(CARxALL) | recruiting | Phase 1 | 20 | OneChain ImmunotherapeuticsINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06326008 | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial | recruiting | Phase 1 | 48 | Beijing GoBroad HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05581030 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06543381 | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | recruiting | Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia(FHD-286) | recruiting | Phase 1 | 33 | Montefiore Medical CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07441980 | A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | recruiting | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05580601 | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432100 | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 20 | Mingfeng ZhaoOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | recruiting | Phase 1 | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
| NCT06287528 | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06950034 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | recruiting | Phase 1 | 105 | Solu Therapeutics, IncINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL(CRETI-NH) | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06580301 | Study of YK012 in B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 46 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07130695 | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | recruiting | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05366218 | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia(Anti-CD19-ALL) | recruiting | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | recruiting | Phase 1 / Phase 2 | 31 | Jacqueline Garcia, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383233 | CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma | not yet recruiting | Phase 1 | 18 | Qi dengOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials